Abstract
Human malignant B-cell tumors arise from a proliferation of a single clone of cells [1]. The immunoglobulin (Ig) which is expressed by the tumor cells is limited to the expression of one single VH and VL region, and to a single light chain. The unique variable region of the Ig, the idiotype, thus forms a specific tumor marker and a potential target for immunotherapy. Levy and colleagues [2] used a monoclonal anti-idiotype antibody to treat a patient with a nodular poorly-differentiated lymphocytic lymphoma, and achieved a complete remission which has lasted so far for 29 months. This group has treated seven more patients with anti-idiotype antibodies but no complete remissions have been obtained [3]. Polyclonal anti-idiotype antibodies raised in sheep have been given to one patient with promyelocytic leukemia [4] and to three patients with lymphoma [5]. There were transient reductions in the level of circulating lymphocytes, but no long-lasting antitumor effect was seen.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Fialkow PJ, Klein E, Klein G and Singh S (1973). Immunoglobulin and glucose-6-phosphate dehydrogenase as markers of cellular origin in Burkitt lymphoma. J Exp Med 138: 89102.
Miller RA, Maloney DG, Warnke T and Levy R (1982). Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306: 517–522.
Lowder JN, Meeker TC, Maloney DG et al. (1984). Anti-idiotype monoclonal antibody therapy of human B-lymphocytic malignancy. Proc Amer Soc Clin Oncol 3: 250.
Hamblin TJ, Abdul-Ahad AK, Gordon J et al. (1980). Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces. Brit J Cancer 42: 495–502.
Macbeth FR, Stevenson FK, Stevenson GT and Whitehouse JMA (1983). Anti-idiotype antibody therapy of patients with non-Hodgkin’s lymphoma. Proceed 2nd Eur Conf Clin Oncol Cancer Nursing. Amsterdam, p. 75.
Smets LA, Taminiau J, Hahlen K et al. (1983). Cell kinetic responses in childhood acute non lymphocytic leukaemia during high-dose therapy with cytosine arabinoside. Blood 61: 79–84.
Mauer AM, Murphy SB, Hayes AB and Dahl GV (1977). Scheduling and recruitment in malignant cell populations. In: Drewinko B and Humphrey EM (Eds.). Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells, pp. 855–864. Baltimore: Williams & Wilkins.
Miller RA, Maloney DG, McKillop J and Levy R (1981). In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukaemia. Blood 58:78–86.
Nadler LM, Stashenko P, Hardy R et al. (1980). Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40: 3147–3154.
Cosimi AB, Burton RC, Colvin RB et al. (1981). Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32: 535–540.
Miller RA, Oseroff AR, Stratte PT and Levy R (1983). Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62: 988–995.
Dillman RO, Shawler DL, Sobol RE et al. (1982). Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukaemia. Blood 59: 1036–1045.
Ball ED, Bernier GM, Cornwell GG et al. (1983). Monoclonal antibodies to myeloid differentiation antigens: In vivo studies of three patients with acute myelogenous leukaemia. Blood 62: 1203–1210.
Zimmerman TS, Godwin HA and Perry S (1968). Studies of leukocyte kinetics in chronic lymphocytic leukaemia. Blood 51: 277–191.
Stepslewski Z, Lubeck MD and Koprowski H (1983). Human macrophages armed with murine immunoglobulin G-2a antibodies to tumours destroy human cancer cells. Science 221: 865–867.
Levy R and Miller RA (1983). Tumor therapy with monoclonal antibodies. Fed Proc 42 2650–2656.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Hekman, A., Rankin, E.M., Somers, R., ten Bokkel Huinink, W. (1985). Therapeutic use of monoclonal anti-idiotype antibodies against B-cell lymphoma. In: Cavalli, F., Bonadonna, G., Rozencweig, M. (eds) Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances. Developments in Oncology, vol 32. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2607-6_59
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2607-6_59
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9632-4
Online ISBN: 978-1-4613-2607-6
eBook Packages: Springer Book Archive